

ISAAC J. POWELL, M.D.

OFFICE ADDRESS: Department of Urology
4201 St Antoine, 7C-UHC
Detroit, MI 48201

EDUCATION:

1958-1962 B.S. (Zoology), University of Michigan, Ann Arbor, MI
1963-1965 M.S. (Embryology), Howard University, Washington, DC
1965-1969 M.D., Indiana University Medical School, Indianapolis, IN

TRAINING:

1969-1970 Internship, Henry Ford Hospital, Detroit, MI
1970-1971 General Surgery Residency, Henry Ford Hospital, Detroit, MI
1971-1974 Urology Residency, Henry Ford Hospital, Detroit, MI

FACULTY APPOINTMENTS:

1980 -1986 Clinical Instructor, Wayne State University, School of Medicine Detroit, MI
1986-1995 Assistant Professor, Department of Urology, Wayne State University School of Medicine, Detroit, MI
1995-2001 Associate Professor, Department of Urology, Wayne State University School of Medicine Detroit, MI
2001-Present Professor, Department of Urology, Wayne State University School of Medicine, Detroit, MI
2001-Present Staff Physician, Wayne State University Physician Group, Detroit, MI

HOSPITAL AND OTHER PROFESSIONAL APPOINTMENTS:

1990-1995 Director of Resident Education, Dept. of Urology
1988-1989 Past President of Michigan Urological Society
1980-1998 Past Board of Directors, Physicians Insurance Company of Michigan, (PICOM)
1980-1998 Past Vice Chairman of the Board and past Chairman of the Underwriting Committee and Risk Management Committee of PICOM
1996-2001 Board of Directors of Professionals Group Inc.
1998-Present Board of Directors of Republic Bancorp Inc.
2004–2007 Residency Program Director, Department of Urology, Wayne State University

MAJOR PROFESSIONAL SOCIETIES:

Wayne County Medical Society
Michigan State Medical Society
Detroit Medical Society / National Medical Center
Michigan Urological Society
American Urological Association
Society of Basic Urologic Research
Society of Urologic Oncology
Southwest Oncology Group (SWOG)
American Cancer Society, National Advisory Group on Prostate Cancer
International Consortium for Prostate Cancer Genetics (I.C.P.C.G.)
American Association Cancer Research #20510

LICENSURE AND BOARD CERTIFICATION:

Licensure State of Michigan #030253
Board Certified: American Board of Urology – 2/5/76, #5773
Fellow, American College of Surgeons

HONORS and AWARDS:

1995 Michiganian of The Year Award
Michigan Cancer Foundation Distinguished Service Award
The MDPH Distinguished Dr. Martin Luther King Award
Centers for Disease Control and Prevention The Department of Health & Human Service:
Outstanding Community Health Promotion Program
1996 Best Doctors
Howard University Cancer Center Award
1998 President's Achievement Award for Community Research
1998 1st International Prostate Cancer Symposium for the patient Medical Professional Advocate Award
2001 American Cancer Award: In Appreciation for the Commitment to Help Find a Cure
2001 Karmanos Partner Award for Prostate Cancer Awareness Ethnic Research
2001-2002 Best Doctors
2003 Crain's Detroit Business Magazine, "Healthcare Hero's": Outstanding Physician Achievement Award.

2003 America's Top Physicians
 2007 Best Doctors
 2011-2016 Best Doctors
 2011 Ambassador Award from Wayne State University School of Medicine
 2012-2013 Best Doctors US News and World Report

SERVICE:

Patient Care

1986-2007 Outpatient and inpatient oncologic urologic care to patients through the hospitals of The Detroit Medical Center and The Barbara Ann Karmanos Cancer Center, the John D. Dingell Veterans Affairs Medical Center and University Physicians Group
 1993-present Prostate Cancer community education outreach
 2007-present Barbara Ann Karmanos Cancer Center and University Physician Group

Journal/Editorial Activity

1998-Present Reviewer: Journal of Urology, Urology, Cancer, Prostate Cancer and Diseases, Urological Oncology, The Prostate, Clinical Cancer Research, Carcinogenesis, British Journal of Urology, American Association of Cancer Research, Journal of Clinical Oncology, International Journal of Cancer
 2011 Department Faculty Development Liaison
 2012-13 5 year review committee of the Pathology Dept.
 2012 5 year review committee of the Urology Dept.

National and International Boards and Committees

1995 CDC Advisory Committee for Prostate and Colorectal Cancer. Consultation on Prostate Cancer Screening Issues
 1995-1998 American Cancer Society: National Advisory Group on Prostate Cancer.
 1996 Chair of Seminar to establish a national collaborative group for Translational prostate cancer research.
 1996 NIH Ad Hoc Study Section: Recruitment strategies for protocols in the African American Community
 1996 Prostate Cancer Study Group Meeting (funded by NIH & CDC). Purpose of Meeting Review of a study design and progress of pilot case-control study on the impact of PSA and digital rectal exam on prostate cancer mortality.
 1998 DOD Study Section: Epidemiology/Behavioral & Social Sciences/Health Care Delivery (EPI/BSS/HCD). Washington National.
 1998 DOD Study Section: United States Army Medical Research and Material Command (USAMRMC), Prostate Cancer Research Program (PCRP), FT Detrick, Maryland.
 1999 International Conference on Prostate Cancer. Program #: 99-175-80, Iowa City, IA.
 1999-2002 Steering committee Johns Hopkins-Howard University Collaboration (NIH-funded).
 2003-Present International Consortium Prostate Cancer Genetics Group.
 2005-2010 External Advisory Board, University Pennsylvania's Center for Population Health and Health

Disparities in Prostate Cancer Outcomes.
 2000-2012 Southwest Oncology Group (SWOG) National Steering Committee Prostate Cancer Prevention Trial
 2007-Present Scientific Advisory Committee, Barbados National Cancer Study
 2004,2008,2010 DOD Prostate Cancer Research Program, Programmatic Review Meeting. (Grant Reviews)

TEACHING:

1. Years at Wayne State: 1986-Present
2. Courses taught at Wayne State in last 5 years

Medical Students –

2005-06 Taught 2nd year Physical Diagnosis on prostate and testicular cancer
 1986-Present Yearly lecture on prostate cancer to second year students

Residents

Present educational lectures and/or participate in discussions regarding those lectures to urology residents and medical students at weekly GU conferences and weekly Urology Grand Rounds Conferences

3. Course or Curriculum Development: Developed curriculum for the urology residency program

GRANT SUPPORT:

1987 Wayne State University Minority Faculty Research, Separation of Human Chromosomes by Flow Cytometry and Characterization by Differential Banding. (\$10,000.00) I Powell, PI.

1987 Urologic Cooperative Oncology Group, A Phase III Trial of Interferon Alfa-2b (Intron-A) As Adjuvant Therapy in Resected Renal Cell Carcinoma of High Risk for Relapse. I Powell, Local PI.

1991-1992 Wayne State University Minority Faculty Research Award Program, Alteration of Proto-Oncogenes/Growth Factor-Related Genes and Tumor Suppressor Genes in Human Prostate Carcinoma and Correlation with Clinical and Pathological Parameters. (\$10,000.00), I Powell, PI.

1993-1995 Office Minority Health, Michigan Department of Public Health, Education and Early Detection of Hypertension and Prostate Cancer in African American Men (\$150,000.00) I Powell, PI.

1994-1996 American Cancer Society Institutional Research Grant, Prostate Cancer Decision-Making among African Americans, I Powell, Co-Investigator.

1995-1998 B8P Loss in Prostate Tumors from White and African American Men. Veterans Administration, (\$346,700.00), I Powell, Co-Investigator.

1995-01 National Cancer Institute Development Grant: Prostate Cancer Progression and Metastasis, (\$1,028,819.00), I Powell, Co-Investigator.

1997-1999 Capture Cure, Genomic Alterations and Cellular Proliferation in Prostate Cancer in African Americans (\$100,000), I Powell, Co-Investigator.

- 1998 Schering Corporation. Adjuvant Immunotherapy for Adenocarcinoma of the Kidney after Radical Nephrectomy, Stage 3 and 4. (\$5,000.00), I Powell, Local PI.
- 1998-2000 Validation of a Semi-Quantitative Food Frequency Questionnaire in a Population of African American Men with Prostate Cancer. (\$60,180.00), I Powell, PI.
- 1998-2004 African American Hereditary Prostate Cancer Study Network; Wayne State University Consortium, Contract with National Cancer Institute and Howard University , (\$3,400,000.00), I Powell, P I of Recruitment Centers (Nationally).
- 1999 U.S. Army, Modeling Differentiation Rates of Increases of Serial PSA in African Americans and Caucasians Following Radical Prostatectomy.
- 1999 – 2002 Department of Health and Human Services, National Institutes of Health, National Cancer Institute Receptor Gene Polymorphisms in Prostate Cancer, Grant No. 1 RO1 CA81240-01A1, Yr. 1 \$216,714, Yr. 2 \$225,868, Yr. 3 \$231,245, I Powell, Co-Investigator.
- 2000-2004 Department of Health and Human Services, National Institutes of Health, Polymorphisms in Prostate Cancer Carcinogenesis (1 RO1 CA84989-01), National Cancer Institute Grant No. 1 RO1 CA81240-01A1, (1,056,575). I Powell, Co-Investigator
- 2003-2004 African American Hereditary Prostate Cancer Study II (National Study – 10 sites). I Powell, National PI of Recruitment Sites.
- 8/1/05-7/31/07 The Office of the Congressionally Directed Medical Research Programs, Analysis of Ethnic Admixture in Prostate Cancer Department of Defense Prostate Cancer Research Program, (\$308.860/year), C Bock, PI, I Powell, Collaborator, 2005.
- 2/11/05-12/31/07 Parexel International Corporation (CRO) for Sanofi-Synthelabo, Inc. Protocol #L8891 – Prospective, observational registry of the Management of Men with Prostate Cancer and a Rising PSA Following Definitive Surgical or Radiological Treatment of the Primary Tumor: PCA Registry COMPARE. I. Powell, PI, (5% effort), \$2,950.
- 1/1/06-12/31/08 Lance Armstrong Foundation. Parexel International: Prospective Observation Registry of Management of Men with Prostate Cancer and Rising PSA Following Definitive Surgical or Radiological Treatment of Primary Tumor (z2884). I. Powell, Co-Investigator (5% effort), \$75,000.
- 5/6/05-4/30/10 NIH/NCI; Grant # 5U01CA114583). CNP for Older Underserved African American Adults. (\$311,938 DC – current 1 yr funding)) T Albrecht, PI; I Powell, Co-Investigator (5% effort).
- 12/01/2000-10/31/2018 NIH/NCI (Mayo Clinic): Grant #2U01CA089600. Prostate Cancer Susceptibility: The ICPCG Study (Sponsor: Translational Genomics Research Institute (TGEN)), \$12,197 (current yr funding); J. Isaac, PI (Johns Hopkins): I. Powell, Local PI (5% effort).
- 4/1/09-3/31/12 DOD: PCO81618; Grant #0483697. The Influence of Metabolic Syndrome on Prostate Cancer Progression and Risk of Recurrence in African-American and European-American Men. I. Powell, PI (15% effort); \$564,375 (Total 3-year Award).

5/1/10-4/30/13 DOD PCO94695; Biochemical and Genetic Markers in Aggressiveness and Recurrence of Prostate Cancer: Race-specific Links to Inflammation and Insulin Resistance. I. Powell, Collaborator (0%). PI I. Podgorski

7/15/12-6/30/17 NIH/NCI: (Dana-Farber Cancer Inst./Broad Inst.) Prime Award #1U01CA162148-01A1. Subaward # 1214001 Systematic Genetic Characterization of African American Prostate Cancer. Sub PI Isaac J. Powell; 168,724.00 (Total 5-year Award). PI Levi Garraway (no salary, contract)

9/30/13-9/29/2016 DOD: MicroRNA and the MicroRNA biosynthesis pathway in prostate cancer racial disparities and aggressiveness. Cathryn Bock, PI: I. Powell Co-investigator, 0%.

National Protocols:

Neoadjuvant Zoladex and Flutamide in Bulky and Non-Bulky Clinical Stage C Carcinoma of the Prostate NCI Protocol: SWOG 9109 Protocol Chairman. **1991**

PUBLICATIONS:

1. **Powell IJ**, Aarons GH: Familial occurrence of the kartagener triad in Jamaica. Postgrad Med J, 45: 736-738, 1969.
2. Klugo RC, Reid R, **Powell IJ**, and Cerny JC: Xanthogranulomatous pyelonephritis in children. J Urol 117: 350-352, 1977.
3. Kansara V, **Powell IJ**: Fibrosarcoma of kidney. Urology 16(4) 419-421, 1980.
4. **Powell IJ**, Cartwright H, Jano F: Villous adenoma and villous adenocarcinoma of the female urethra. Urology 18(6):612-16, 1981.
5. Kleer E, **Powell IJ**, Tyrkus M: Importance of marker chromosomes in superficial transitional cell carcinoma of bladder: 50 patients followed up to 17 years, by W.H. Falor and R.M. Ward-Skinner. Letter to the editors published in J Urol 142: 1333. 1989.
6. **Powell IJ**, Tyrkus M Kleer E: Apparent correlation of sex chromosome loss and disease course in urothelial cancer. Cancer Genet Cytogenet 50:97-101, 1990.
7. Tyrkus M, **Powell IJ** & Sakr, W.: Cytogenetic studies of CIS of the bladder: Prognostic implications. J Urol 148: 89-95, 1992.
8. Macoska J, **Powell I**, Sakr W, and Lane MH: Loss of 17P Chromosomal region in a metastatic carcinoma of the prostate. J Urol 147: 1142-1146, 1992.
9. Micale MA, Mohammed A. Sakr W, **Powell IJ**, and Wolman SR: Cytogenetics of primary prostatic adenocarcinoma - clonality and chromosome instability. Cancer genetics and cytogenetics, 61: 165-173, 1992.
10. Micale MA, Sanford JS, **Powell IJ**, Sakr WA, Wolman SR: Defining the extent and nature of cytogenetic events in prostatic adenocarcinoma: Paraffin FISH vs. metaphase analysis. Cancer Genet Cytogenet 69: 7-12, 1993.

11. Younes E, Haas GP, Montie JE, Smith JB, **Powell IJ**, and Pontes JE: Value of preoperative PSA in predicting pathological stage of patients undergoing salvage prostatectomy. *Urology* 43(1):1334-8 1994.
12. Hussain MH, **Powell IJ**, Zaki N, Maciorowski Z, Sakr W, Kukuruga M, Visscher D, Haas GP, Pontes JE, Ensley JF: Flow Cytometric DNA analysis of fresh prostatic resections: Correlation with conventional prognostic parameters in patients with prostate cancer. *Cancer* 72(10): 3012-3019, 1993.
13. Meloni A, Peier A, Haddad F, **Powell I**, Block A, Huben R, Todd I, Potter W, and Sandberg A: FISH analysis of urine, bladder washings and tumors - A new approach in the diagnosis and follow-up of bladder cancer. *Cancer Genet Cytogenet* 71: 105-118, 1993.
14. **Powell IJ**: Early detection issues of prostate cancer in African American men. *In Vivo* 7:1, 1994.
15. Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, **Powell, IJ**, Pontes JE: Fluorescence *in situ* hybridization (FISH) analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. *Cancer Res* 54(15): 3824-3830, 1994.
16. Bukowski TP, Chakrabarty A, **Powell IJ**, Frontera R, Perlmutter AD, Montie JE: Acquired rectourethral fistula - methods of repair. *J. of Urology*, Vol. 153, 730-733, March 1995.
17. **Powell IJ**, Gelfand DE, Parzuchowski J, Heilbrun L, Franklin A: A successful recruitment process of African American men for early detection of prostate cancer. *Cancer (Suppl)* (**need vol #**) 1880-84, 1995.
18. Gelfand DE, Parzuchowski J, Cort M, **Powell IJ**: Digital rectal examinations and prostate cancer screening: attitudes of African-American men. *Oncol Nursing Forum* 22(8): 1253-1255, 1995.
19. **Powell IJ**, Schwartz K, Hussain MH: Equity in financial access to health care: Does it impact prostate cancer stage at presentation and survival? A comparative study between black and white males in a VA system. *Urology* 46: 825-830, 1995.
20. Gao X, Grignon DJ, Chbihi T, Zacharek A, Chen YQ, Sakr W, Porter AT, Crissman JD, Pontes JE, **Powell IJ**, Honn KV: Elevated 12-Lipoxygenase mRNA Expression correlates with advanced stage and poor differentiation of human prostate cancer. *Urology* 46: 227-237, 1995.
21. Gao X, Zacharek A, Grignon DJ, Sakr W, **Powell IJ**, Porter AT, Honn KV: Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer. *Oncogene* 11: 1241-1247, 1995.
22. Sakr WA, Grignon DJ, Haas GP, Schomer KL, Heilbrun LK, Cassin BJ, **Powell IJ**, Montie JB, Pontes JE, Crissman JD: Epidemiology of high grade prostatic intraepithelial neoplasia. *Pathology Res Prac* 191: 842-849, 1995.
23. Macoska JA, Trybus TM, Benson PD, Sakr WA, Grignon DJ, Wojno KD, Pietruk T, **Powell IJ**: Evidence of three tumor suppressor gene loci on chromosome 8p in human prostate cancer. *Cancer Res* 55: 5390-5395, 1995.
24. Sakr WA, Grignon DJ, Haas GP, Schomer KL, Heilbrun LK, Cassin BJ, **Powell IJ**, Montie JE, Pontes JE, Crissman JD. Epidemiology of High grade prostatic intra epithelial neoplasia. *Path Res Prac* 191: 838-841, 1995.

25. Sakr WA, Grignon DJ, **Powell IJ**, Ritchie CA, Schomer KL, Ottosen SF, Heilbrun LK, Montie JE, Pontes JE and Crissman JD. Clinically localized prostatic carcinoma (PCa) in white and Afro-American (AA) males: A detailed morphologic and flow cytometric study. *Modern Pathol* 8: 82 -84, 1995.
26. Chopra DP, Grignon DJ, Joiakim A, Mathier PA, Mohammed A, Sakr WA, **Powell IJ**, Sarkar FH: Differential Growth Factor responses of epithelial cell cultures derived from normal human prostate, benign prostatic hyperplasia and primary prostate carcinoma. *J Cell Physiol* 169: 269-280, 1996.
27. Boehm S, Coleman-Burns P, Schlenk EA, Funnell MM, Parzuchowski J, **Powell IJ**: Prostate cancer in African American men: Increasing knowledge and self-efficacy. *J Community Health Nurs.* 12(3):161-9. 1995.
28. Honn KV, Aref A, Chen TQ, Cher ML, Crissman JD, Forman JD, Gao X, Grignon D, Hussain M, Porter AT, Pontes JE, **Powell IJ**, Redman B, Sakr W, Severson R, Tang DG, Wood DP: Prostate cancer old problems and new approaches. *Path Oncol Res* 2:1-2, 1996.
29. Forman JD, Jonathan R, Parzuchowski J, Littrup P, Porter AT, **Powell, IJ**: Earlier detection of prostate cancer in African American men treated with radiotherapy: Results of a targeted screening program. *Rad Oncol Invest* 4: 80-82, 1996.
30. Montie JE, Pontes JE, **Powell IJ**: A comparison of the w-stapled ileal reservoir with hand-sewn reservoirs for orthotopic bladder replacement. *Urology* 47: 476-481, 1996.
31. **Powell IJ**, Heilbrun L, Littrup P, et al: Outcome of African American Men screened for prostate cancer the DEED (Detroit Education and Early Detection) Study. *J Urol* 158: 146-149, 1997.
32. **Powell IJ**, Heilbrun L, Sakr W, Grignon D, Montie JE, Novallo M, Smith D, Pontes JE: The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: A multivariate analysis of positive surgical margins. *Urology* 49:726-731, 1997.
33. **Powell IJ**: Prostate Cancer and African American Men. *Oncology* 11: 599-605, 1997. (Review Article)
34. **Powell IJ**, Banerjee M, Sakr W, Grignon D, Novallo M, Wood DP, Pontes E: Should African American men be tested for prostate cancer at an earlier age than Caucasian men? *Cancer* 85: 472-477, 1999.
35. Cher ML, Lewis PE, Banerjee M, Sakr W, Grignon DJ, **Powell IJ**: Similar pattern of chromosomal alteration in prostate cancers from African Americans and Caucasian Americans. *Clini Cancer Res.* 4: 1273-1278, 1998.
36. Barroso U, Oskanian P, Tefilli M, Banerjee M, Grignon D, Sakr W, Pontes JE, **Powell IJ**. Population-based study of pelvic lymph node positivity in clinically localized prostate cancer: a study comparing African Americans and whites. *Urology* 53(1): 187-191, 1999.
37. Tiguert R, Gheiler LE, Tefilli MV, Banerjee M, Grignon DJ, Sakr W, Wood DP, **Powell IJ**, Pontes JE: Racial differences and prognostic significance of tumor location in radical prostatectomy specimens. *Prostate* 37, (need page or vol #) 1998.
38. **Powell IJ**: Prostate cancer among African American men- from the bench to the community. *J Natl Med Assoc* 90(1) 705-709, 1998.

39. Wood DP, Beaman A, Banerjee M, **Powell I**, Pontes E, Cher ML: Effect of neoadjuvant deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy. Clin Cancer Res 4: 2119-2123, 1998.
40. **Powell IJ**: Prostate cancer in the African American: Is this a different disease? Sem Urologic Oncol 16(4): **(need pg #)**, 1998.
41. Gheiler EL, Lovisolo JA, Tiguert R, Tefilli MV, Grayson T, Oldford G, **Powell IJ**, Famiglietti G, Banerjee M, Pontes EJ, Wood DP: Results of a clinical care pathway for radical prostatectomy Patients in an open hospital-multi physician system. Eur **(NAME OF JOURNAL)** 35: 210-216, 1999.
42. Barroso U, Oliveira J, Barroso V, Pontes J, **Powell I**: Diferencas no comportamento epidemiologico do cancer de prostata em negros e brancos Americanos. Journal Brasileiro de Urologia, 25(1): 53, 1999.
43. **Powell IJ**, Banerjee M, Novallo M, Sakr W, Grignon D, Wood DP, Pontes JE: Should the age specific PSA cut-point for prostate biopsy be higher among African American vs. Caucasian men above 50 years. J Urol 163: 146-149, 2000.
44. Sakr WA, Grignon DJ, **Powell IJ**, Banerjee M, Littrup PJ, Wood DP, Crissman JD, Pontes JE: Clinical and pathologic characteristics of T1C prostate cancer in African American and Caucasian patients treated by radical prostatectomy. Urology 55: 899-903, 2000.
45. **Powell IJ**, Banerjee M, Novallo M, Sakr W, Grignon D, Wood DP, Pontes JE: Prostate cancer biochemical recurrence stage for stage is more frequent among African American versus Caucasian men with locally advanced but not organ confined disease. Urology 55: 246-251, 2000.
46. .Shekarriz B, Tiguert R, Gheiler E, Upadhyay J, **Powell J**, Pontes J, Grignon D, Wood D: Impact of location and multifocality of positive surgical margins on disease free survival following radical prostatectomy: A comparison between African American and Caucasian men. Urology 55: 899-903, 2000.
47. Narain V, Tiguert R, Banerjee J, Sakr W, Grignon D, Wood DP, Pontes JE, **Powell IJ**: Biochemical recurrence in African American and Caucasian men with a positive and negative family history of prostate cancer following radical prostatectomy. J Urol 165: 474-477, 2001.
48. Washburn JE, Wojno KJ, Dey J, **Powell IJ**, Macoska JA: 8pter-p23. Deletion is associated with racial differences in prostate cancer outcomes. Clin Cancer Res 6: 4647-4652, 2000.
49. Royal C, Baffoe-Bonnie H, Kittles R, **Powell IJ**, Bennett J, Hoke G, Pettaway C, Dunston G, Collins F, et al: Recruitment experience in the first phase of the African American hereditary prostate Cancer (AAHPC) study. Ann Epidemiol. 10: 568-577, 2000.
50. Sakr W, Tefilli MV, Grignon DJ, Banerjee M, Jey J, Gheiler EL, **Powell IJ**, Wood DP: Gleason score 7 prostate cancer: A heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 56: 730-734, 2000.
51. **Powell IJ**, Meykens FL: African American males and hereditary/familial prostate cancer: intermedicate risk population for chemoprevention trials. Urology 57(Suppl): 178-181,2001.

52. **Powell IJ**, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu CA, Boykin W, Mason T, Royal C, Baffoe-Bonnie A, Bailey-Wilson J, Berg K, Trent J, Collias F: African American hereditary prostate cancer study: a model for genetic research. *J Natl Med Soc* 93: 120-123, 2001.
53. **Powell IJ**, Dey J, Pontes EJ, Cher ML, Sakr W, Wood DP: Disease free survival of local prostate cancer among African Americans and Caucasians: A multivariable analysis of race/ethnicity as an independent variable. *Urology* 59: 907-912, 2002.
54. Banerjee M, **Powell J**, George J, Biswas D, Bianco F, Severson RK: Prostate Specific Antigen Progression following Radical Prostatectomy in African American versus Caucasians. *Cancer* 94:2577-2583, 2002.
55. **Powell IJ**. Prostatectomy between African Americans and Caucasian men. *J Urol* 168, 479-482, 2002.
56. **Powell IJ**, Tangen M, Miller G, Lowe B, Haas G, Carroll PR: Neoadjuvant therapy prior to radical Prostatectomy for clinical T3/T4 carcinoma of the prostate (5-year follow-up, Phase II SWOG Study 9109) *J Urol* 168:2016-2019, 2002.
57. Bianco FJ, **Powell IJ**, Cher MJ, Wood DP: Presence of Circulating Prostate Cancer Cells in African American Males Adversely Affect Survival. *Urol Oncol* 7: 147-152, 2002.
58. Weinrich SP, Royal C., Pettaway CA., Dunston G, Faison-Smith L., Hudson J, Roberson- Smith P, Frost J, Jenkins J, Brooks KA, **Powell, I.** (2002). Interest in prostate cancer susceptibility testing among African American men. *Cancer Nursing* 25(1): 28-34, 2002.
59. Weinrich SP, Faison-Smith L, Hudson-Priest J, Royal C, **Powell, I.** Stability of self-reported family history of prostate cancer among African American Men. *J Nursing* 10: 39-46, 2002.
60. Bianco FJ, Wood DP Jr, Grignon DJ, Sakr WA, Pontes JE, **Powell IJ**. Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy. *J Urol* 168(2): 479-482, 2002.
61. Bianco FJ Jr, Wood DP Jr, Cher ML, **Powell IJ**, Souza JW, Pontes JE: Ten-Year survival after radical prostatectomy: specimen gleason score is the predictor in organ-confined prostate cancer. *Clin Prostate Cancer* 1: 242-247, 2003.
62. Bianco FJ, Kattan MW, Scardino PT, **Powell IJ**, J. Edson Pontes, David P. Wood, Jr: Radical Prostatectomy Nomograms in Black American Men: Accuracy and applicability. *J Urol* 170: 73-77, 2003.
63. **Powell IJ**, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahahotu CA, Boykin W, Mason T, Royal C, Baffoe-Bonnie A, Bailey-Wilson J, Berg K, Trent J, Collins F: High-grade intra-epithelial neoplasia and prostate cancer in Dibombari, Cameroon. *Prostate Cancer Prostatic Dis.* 6(1): 34-38 2003
64. Ahoghotu CA, Baffoe-Bonnie A, **Powell IJ**, Kittles R, Royal C, Wang H, Vijayakumar S, Bennett J, Hoke G, Mason T, Bailey-Wilson J, Boykin W, Berg K, Carpten J, Weinrich S, Trent J, Dunston G, Collins F and Pettaway C: Clinical characteristics of african american men with hereditary prostate cancer: The AAHPC Study. *Prostate Cancer Prostatic Dis* 7: 165-169, 2004.

65. **Powell I**, Land SJ, Dey, J, Heilbrun LK, Hughes MR, Sakr WA, Everson RB. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after radical prostatectomy. *Cancer* 103(3): 528-537, 2005.
66. Williams H, **Powell IJ**, Sakr WA, Weng C, Butler C, Land CJ, Patel NP, Heilbrun LK, Hughes MR, Everson RB: Impact of vitamin D receptor bsmi polymorphism on prostate cancer recurrence after radical prostatectomy in African American and Caucasian men. *The Prostate* 62:267-275, 2004.
67. **Powell IJ**, Zhou JY, Sun Y, Sakr WA, Patel NP, Heilbrun LK, Everson RB. CYP3A4 genetic variant and disease free survival among Caucasian and African American men after radical prostatectomy. *J Urol* 172 (5, Part 1 of 2): 1848 -1852, 2004.
68. **Powell IJ**, Banerjee M, Bianco FJ, Wood DP Jr., Dey J, Lai Z, Heath M, Pontes EJ: The effect of race/ethnicity on prostate cancer treatment outcome is conditional: A review of Wayne State University data. *J Urol* 171:1508-1512, 2004.
69. Kittles RA, Baffoe-Bonnie AB, Collins FS, Dunston G, **Powell IJ**, Carpten JD: A common nonsense mutation in ephb2 is associated with prostate cancer risk in African American men with a positive family history. *J Med Gen*, 43:507-511, 2005.
70. Bangsi D, Zhou JY, Sun Y, Patel NP, Darga LL, Heilbrun LK, **Powell IJ**, Severson RK, and Everson RB: Impact of Genetic Variant in CYP3A4 on Risk and Clinical Presentation of Prostate Cancer Among White African-American Men. *Urol Oncol*, 177: 149-152 2005.
71. Fisher M, Andrew WJ, **Powell, IJ**: Breast carcinoma metastatic to the bladder and renal pelvis Requiring gulguration. *Clin Breast Cancer* 54: 173-174, 2005.
72. Weinrich S, Weinrich M, Pettaway C, Vijayakumar S, **Powell IJ**: Prostate cancer screening in high risk men. African American hereditary prostate cancer study network. *Amer Cancer Soc* 68: 1072-1076, 2006.
73. Altinok G., **Powell IJ**, Che MX, Hormont K., Sarkar FH, Sakr WA, Grignon D, Liao DJ. 2005 Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma. *Prostate Cancer Prostatic Dis.* 9: 77-82, 2006
74. Baffoe-Bonnie A, Kittles RA, Gillanders E, Ou L, George A, Ahaghotu C, Bennett J, Boykin W, Hoke G, Mason T, Pettaway C, Vijayakumar S, Weinrich S, Jones MP, Lockwood E, Klaric M, Faruque M, Royal C, Trent JM, Berg K, Collins FS, Fubert-Harris P, Bailey-Wilson JE, Dunston G, **Powell I**, Carpten JD: Genome-wide linkage of 77 families from the African American hereditary prostate cancer study (AAHPC). *Prostate* 67: 22-31, 2006.
75. Bangsi D, Zhou J, Sun Y, Pael NP, Dargo LL, Heilbrun LK, **Powell IJ**, Severson RK, Everson RB. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. *Urol Oncol* 24(1): 21-27, 2006.
76. Vaishampayan U, Forman J, Cher M, Hussain M, Banerjee M, Fontana J, **Powell IJ**, Pontes JE, Sarkar F, Kucuk O. Lycopene and soy isoflavones in the treatment of prostate cancer. *Nutrition and Cancer* 59: 1-7 2007.

77. Yanke BV, Carver BS, Bianco FJ Jr, Simoneaux WJ, Venable DD, **Powell IJ**, Eastham JA. African-American race is a predictor of prostate cancer detection: Incorporation into a pre-biopsy nomogram. *Brit J Intl* 98(4): 783-787, 2006.
78. Holmes MD, **Powell IJ**, Campos J, Stampfer MJ, Giovannucci EL, Willett WC. Validation of a food frequency questionnaire measurement of selected nutrients using biological markers in African-American men. *Euro J Clin Nutri* 61(11): 1328-1336, 2007.
79. Weinrich S, Vjayakumar S, **Powell IJ**, Priest J, Hamner CA, McCloud L, Pettaway C. Knowledge of hereditary prostate cancer among high-risk African American men. *Oncol Nurs Forum* 34(4): 854-860, 2007.
80. **Powell IJ**. Epidemiology and pathophysiology of prostate cancer in African American Men. *J Urol* 177: 444-449, 2007.
81. **Powell IJ**. Race biochemical disease recurrence and prostate-specific antigen doubling time in the search database. *Cancer* 110 (10): 2153-2154, 2007.
82. Camp NJ, Cannon-Albright LA, Farnham JM, Baffoe-Bonnie AB, George A, **Powell IJ**, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girva I, Sheih C-I, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebbing S, Schaid DJ, Lange EM, Cooney KA, Tamela TLJ, Schleutker J, Paiss T, Maier C, Gronberg H, Wiklund F, Emanuelsson M, Issacs WB. Comparing Evidence for a Prostate Cancer Gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. *Human Molecular Genetics* 16(11) 1271-78 2007
83. Heath EL, Kattan MW, **Powell IJ**, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ. The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. *Urology* 71(1): 151-155, 2008.
84. Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T, Pettaway CA, Vijayakumar S, Weinrich S, Furbert-Harris P, Dunston G, **Powell IJ**, Carpten JD, Kittles RA. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. *Prostate* 68(16): 1790-1797, 2008.
85. Weinrich SP, Seger RE, Rao GS, Chan EC, Hamm RM, Godley PA, Moul JW, **Powell I**, Chodak GW, Taylor KL, Weinrich MC. A decision aid for teaching limitations of prostate cancer screening. *J Natl Black Nurses Assoc* 19(1): 1-11, 2008.
86. Ellison G, Weinrich S, Lou M, Xu H, **Powell IJ**, Baquet CR. A randomized trial comparing web-based decision aids on prostate cancer knowledge for African American men. *J Natl Med Assoc* 100(10): 1139-1145, 2008.
87. Williams H, **Powell IJ**. Epidemiology, pathology and genetics of prostate cancer among African Americans compared with other ethnicities. *Methods Mol Biol* 472: 439-453 (Rev), 2009.
88. Thompson I, Tangen C, **Powell IJ**, Bruce L, Hass G, Carroll PR, Canby-Hagino E, deVere White R, Crawford DE. Long-term follow-up of neoadjuvant therapy prior to radical prostatectomy for clinical T3/T4 prostate cancer. *J Urol*, in press.

89. Wideroff L, Philips K, Randhawa G, Ambs A, Armstrong K, Bennett CL, Brown ML, Donaldson MS, Follen M, Goldie SJ, Hiatt RA, Khoury MJ, Graham L, McLeod H, Piper M, **Powell I**, Schrag D, Schulman KA, Scott J. A health services research agenda on cellular molecular and genomic technologies in cancer care. *J Natl Cancer Inst, Public Health Genomics* 2009;12:233-244 (DOI:10.1159/000203779)
90. Schwartz K, **Powell IJ**, Underwood W, George J, Yee C, Banerjee M. Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. *Urology*. 2009 Dec; 74(6): 1296-302. PMID; 19962532
91. **Powell IJ**, Bock CH, Ruterbusch JJ, Sakr W. "Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men and influence racial progression and mortality disparity." *J. of Urol*. 2010 May; 183(5): 1792-6. Epub 2010 Mar. 17.
92. Bock CH, Schwartz AG, Ruterbusch JJ, Levin AM, Neslund-Dudas C, Land SJ, Wenzlaff AS, Reich D, McKeigue P, Chen W, Heath EL, **Powell IJ**, Kittles RA, Rybicki BA. Results from a prostate cancer admixture mapping study in African American men. *Hum Genet*. 2009 Nov; 126(5):637-42. Epub 2009 Jul 1. PMID: 19568772
93. Christensen GB, Baffoe-Bonnie AB, George A, **Powell I**, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Thibodeau SN, McDonnell SK, Hebbbring S, Schaid DJ, Lange EM, Cooney KA, Tammela TL, Schleutker J, Paiss T, Maier C, Grönberg H, Wiklund F, Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. Emanuelsson M, Farnham JM, Cannon-Albright LA, Camp NJ; Consortium for Prostate Cancer Genetics. *International Prostate*. 2010 May 15;70(7):735-44.
94. Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM, Cooney KA, Farnham JM, Camp NJ, Cannon-Albright LA, Tammela TL, Schleutker J, Hoegel J, Herkommer K, Maier C, Vogel W, Wiklund F, Emanuelsson M, Grönberg H, Wiley KE, Isaacs SD, Walsh PC, Helfand BT, Kan D, Catalona WJ, Stanford JL, Fitzgerald LM, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Thibodeau SN, McDonnell SK, Hebbbring S, Schaid DJ, Whittemore AS, Oakley-Girvan I, Hsieh CL, **Powell I**, Bailey-Wilson JE, Cropp CD, Simpson C, Carpten JD, Seminara D, Zheng SL, Xu J, Giles GG, Severi G, Hopper JL, English DR, Foulkes WD, Maehle L, Moller P, Badzioch MD, Edwards S, Guy M, Eeles R, Easton D, Isaacs WB; International Consortium for Prostate Cancer Genetics. *Prostate. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPG* 2012 Mar;72(4):410-26. doi: 10.1002/pros.21443. Epub 2011 Jul 11.
95. **Powell IJ**. Editorial:Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. *BJU Int*. 2011 Oct;108(7):1092. doi: 10.1111/j.1464-410X.2011.10541.x. No abstract available.
96. **Powell IJ**. The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis. *Arch Esp Urol*. 2011 Oct;64(8):711-9. English, Spanish.
97. Bock CH, **Powell I**, Kittles RA, Hsing AW, Carpten J. Racial disparities in prostate cancer incidence, biochemical recurrence, and mortality. *Prostate Cancer*. Vol. 2011;2011:716178. Epub 2011 Dec 13. No abstract available

98. Kong D, Heath E, Chen W, Cher M, **Powell I**, Heilbrun L, Sarkar F, et al. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. *Am J Transl Res*: 2012;4(1):14-23.
99. Kong D, Heath E(03), Chen W(02), Cher ML(01), **Powell I(04)**, Heilbrun L(03), Li Y, Ali S, Sethi S(03), Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA(01), Menon M, Sarkar FH(01). Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM. *PLoS One* 2012;7:e33729. PMID: PMC3307758
100. Berglund RK, Tangen C, **Powell I**, Lowe B, Haas G, Carroll P, Hagino E, deVere White R, Hemstreet G, Crawford D, Thompson I, Klein E. Ten-year follow-up of Neoadjuvant therapy with goserelin acetate and flutamide prior to radical prostatectomy for clinical T3 and T4 prostate cancer. SWOG group study 9109 *Urology*: 2012; 79(3): 633-637.
101. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, **Powell IJ**, Thompson IM Jr. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). *J Urol*. 2012 Oct;188(4)
102. Bailey-Wilson JE, Childs EJ, Cropp CD, Schaid DJ, Xu J, Camp NJ, Cannon-Albright LA, Farnham JM, George A, Powell I, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Mæhle L, Møller P, Eeles R, Easton D, Guy M, Edwards S, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Stanford JL, Karyadi DM, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebring S, Lange EM, Cooney KA, Tammela TL, Schleutker J, Maier C, Bochum S, Hoegel J, Grönberg H, Wiklund F, Emanuelsson M, Cancel-Tassin G, Valeri A, Cussenot O, Isaacs WB; Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. International Consortium for Prostate Cancer Genetics. *BMC Med Genet*. 2012 Jun 19;13:46. doi: 10.1186/1471-2350-13-46. PMID: 22712434 [PubMed - indexed for MEDLINE]
103. Xu, J. F., Lange, E. M., Lu, L. Y., Zheng, S. Q. L., Wang, Z., Thibodeau, S. N., Cannon-Albright, L. A., Teerlink, C. C., Camp, N. J., Johnson, A. M., Zuhlke, K. A., Stanford, J. L., Ostrander, E. A., Wiley, K. E., Isaacs, S. D., Walsh, P. C., Maier, C., Luedeke, M., Vogel, W., Schleutker, J., Wahlfors, T., Tammela, T., Schaid, D., McDonnell, S. K., DeRycke, M. S., Cancel-Tassin, G., Cussenot, O., Wiklund, F., Gronberg, H., Eeles, R., Easton, D., Kote-Jarai, Z., Whittemore, A. S., Hsieh, C. L., Giles, G. G., Hopper, J. L., Severi, G., Catalona, W. J., Mandal, D., Ledet, E., Foulkes, W. D., Hamel, N., Mahle, L., Moller, P., **Powell, I.**, Bailey-Wilson, J. E., Carpten, J. D., Seminara, D., Cooney, K. A., Isaacs, W. B., Int Consortium Prostate Canc, *Genet (2013) HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)*. *HUMAN GENETICS*, 132 (1). pp. 5-14. ISSN 0340-6717
104. **Powell, I. J.**, Dyson G, Land S, Ruterbusch J., Bock C. H., Lenk S, Everson R, Giroux C. N., Schwartz A.G., Bollig-Fisher A Genes associated with prostate cancer are differentially expressed in African American and European American men. *Cancer Epidemiology Biomarkers and Prevention*, 2013;22:891-897.
105. **Powell, I.J.**, Bollig-Fisher, A: The molecular and genomic basis for prostate cancer health disparities. *Molecular Endocrinology*, 2013 27: 879-891.
106. Moul, J.W., Walsh, P.C., Rendell, M.S., Lynch, H.T., Leslie, S.W., Kosoko-Lasaki, O., Fitzgibbons, W.P., **Powell, I.J.**, D'Amico, A.V., Catalona, W.J.: Letter to the Editor: Re: Early Detection of Prostate Cancer: AUA guideline: *J. of Urology*, 2013 190:1134-1142.

107. **Powell, I.J.**, Vigneau, F.D. Bock, C, Ruterbusch, J., Heilbrun L.K.: Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American Men. *Cancer Epidemiology Biomarkers and Prevention*, 2014: 23: 1505-1511.

108. **Powell, I.J.**, Dyson, G., Sreenivasa, C.R., Bollig-Fischer, A.: Race influences the potential for ERG expression as a biomarker for prostate cancer. *Personalized Medicine*: 2014: 11(4) 409-412.

109. **Powell, I.J.**: Editorial Comment: Re: Racial Disparities in Oncologic Outcomes After Radical Prostatectomy: Long-term Follow-up: *Urology* 2014 Dec; 84 (6):1441

BOOK CHAPTERS:

1. Powell IJ: *Epidemiology in African Americans: "Advanced Therapy of Prostate Disease"*, BC Decker Inc, Hamilton, London, 2000, pp 6-13.
2. Powell IJ: *Race and Risk: "Prostate Cancer: Principles and Practice"*. Lippincott, Williams & Wilkens, Philadelphia PA, 2002, pp 162-174.
3. Powell IJ: *Prostate Cancer Treatment Outcome between African Americans and Caucasians: "Prostate Cancer, Science and Clinical Practice"* Academic Press Ltd, San Diego, CA, 2003, pp 137-144..
4. Powell IJ: *The Special Problems of Prostate Cancer Among African Americans: Clinical and Molecular Factors: "Management of Prostate Cancer"*. Humana Press Incorporated, Totowa, New Jersey 2004, pp 107-119.
5. Powell IJ: *Epidemiology, Pathophysiology and Genetics of Prostate Cancer in AAM Men Affiliation"*, Springer-Verlag, 2008, in press.
6. Powell IJ: *"Epidemiology, Pathophysiology And Genetics Of Prostate Cancer Among African Americans Compared To Other Ethnicities"*, Humana Press Incorporated, Totowa, New Jersey, 2008 *Methods Mol Biol.* 2009;472:439-53. Review. PMID: 19107447
7. Powell IJ: *"African American Populations: Inherited Susceptibility For Prostate Cancer"* , Springer Science and Business Media, 2008, in press.

PUBLISHED ABSTRACTS:

1. Tyrkus M, **Powell IJ**, Guy M: Chromosomal changes in long-term TCC culture: Predictive value. *Genetics.* 39(3): A45, 1986.
2. **Powell IJ**, Tyrkus M, Ghayad P, Guy W, Pierce JM Jr: Cytogenetics: Use in prognosis and management of bladder cancer. *J Urol* 137 (Abstr), April 1987.
3. **Fleming CJ**, Powell IJ, Tyrkus M, Crissman JD, Zarbo RJ, Pierce JM Jr: Comparison of cytogenetics and flow cytometry in transitional cell carcinoma. *J Urol* 139 (Abstr), April 1988.
4. **Powell IJ**, Tyrkus M, Ghayad P, Guy W, Pierce JM Jr: Cytogenetics of urothelial carcinoma *in situ*: An important determinant in prognosis. *J Urol* 139 (Abstr), April 1988.
5. **Powell IJ**, Tyrkus M: Loss of the sex chromosome in bladder cancer. Is there a clinical significance? *J Urol*, 141 (Abstr), April 1989.

6. **Powell IJ**, Everson R, Fisher M, Banerjee M. African American Men, Ages 40-59, unlike Caucasian men, present with as aggressive PCA as older African Americans: A genetic explanation. J Urol 173(Suppl 4), (Abstr) #268, 2005.
7. **Powell IJ**, Fisher M, Sun Y, Everson R. Macrophage scavenger receptor 1 gene (MSR-1) polymorphisms and progression after prostatectomy. J Urol 173(Suppl 4): Abstr #1410,2005.
6. **Powell IJ**, Tyrkus M, Gohle N: Cytogenetic studies of TCC of the bladder: Correlations of karyotype, aggressive nature and disease course. Amer J Human Genet 45(4): (Abstr), 1989.
7. Tyrkus M, **Powell IJ**: Cytogenetic studies of carcinoma *in situ* (CIS) of the bladder. Amer J Human Genet 47(3): (Abstr), September 1990.
8. Wolman SR, Mohammed A, Micale M, Macoska J, Lane MA, **Powell IJ**: Cytogenetic and molecular studies of primary prostatic adenocarcinomas. 4th Intl Workshop on Chromosomes in Solid Tumors, Tucson, AZ, 1991 (Abstr)
9. Macoska JA, Micale MA, Mohammed A, **Powell, IJ**, Lane MA, Wolman SR: Molecular genetic and karyotypic alterations in prostate carcinoma. Proceedings of the 8th Intl Congress of Human Genetics, Abstr #1340 Washington, DC, October, 1991.
10. **Powell IJ**, Gimotty P, Wolman SR, Micale MA, Betrus G, Pontes JE: Clinical and cytogenetic correlations and trends in prostate cancer. J. Urol.147(4): (Abstr), 1992.
11. **Powell IJ**, Gelfand D, Parzuchowski J, Franklin A, Montie J: Overcoming barriers to early detection in the African American Community; (DEED Program: Detroit Education and Early Detection). J. Urol 151(5): (Abstr), May 1994.
12. **Powell IJ**, Schwartz K, Hussain M: Stage of presentation of African American and Caucasian men with prostate cancer at a VA Hospital. Amer Urologic Soc Mt, J. Urol.151(5): (Abstr), May 1994.
13. **Powell IJ**, Kumar A, Montie JE, Haas GP, Sakr W, Grignon D, Heilbrun L, Pontes JE: Prognostic factor variations between African American Men and Caucasian Men with clinical localized prostate carcinoma. J. Urol 151(5): (Abstr), May 1994.
14. Pontes JE, Montie JM, Haas G, **Powell IJ**, Sakr W, Grignon D: Earlier detection of radiation failure and proper surgical selection decreases complication rate in salvage prostatectomy. J. Urol 151(5): (Abstr), May 1994.
15. Montie JM, Pontes JE, **Powell IJ**: Orthotopic ileal neobladder_after cystectomy: Comparison of hand-sewn vs. absorbable staples for reservoir formation. J. Urol.153 (4): (Abstr) 1995.
16. **Powell IJ**, Gelfand D, Heilbrun L, Parzuchowski J, Franklin A: Results of early detection of prostate cancer in 1,100 African American men. Deed program update. J. Urol 153(4): (Abstr), April, 1995.
17. **Powell IJ**, Heilbrun L. Sakr W. Grignon D, Montie J, Novallo M, Pontes JE: Multi variate analysis of clinical prognostic factors in a black and white racial population with clinically localized prostate cancer. J Urol 153(4): (Abstr #430A), 1995.

18. Fesseha T, Pontes JE, Montie JM, Haas GP, **Powell IJ**, Grignon D, Sakr W: Prognostic significance of a positive apical margin in radical prostatectomy specimens. J Urol 153(4): (Abstr), 1995.
19. Littrup PJ, Sparschu RA, **Powell IJ**, Pontes JE: Cost-effective biopsy strategies: racial, clinical and screening differences. J Urol, Vol. 155, (5): (Abstr), 1996.
20. Klink JC, Bañez LL, **Powell IP**, Aronson WJ, Terris MK, Kane CJ, Amling CL , Freedland SJ. T1C Disease in black men: a more aggressive disease? Results from the SEARCH database group. Soc Urol Oncol (Abstr), 2007
20. Littrup PJ, Klein RM, Gross ML, Sparschu RA, **Powell IJ**: Color doppler guides prostate biopsies to higher grade cancers: racial implications. J Urol, Vol. 155, (5): (Abstr), 1996.
21. Littrup PJ, Cowen M, Kattan M, **Powell IJ**, Sakr WA: Racial differences in the volumes of Gleason score components: the potential for mathematical modeling of mortality differences and screening impact. J Urol 157(4): (Abstr), April 1997.
22. Sakr WA, Grignon DJ, Lovisolo J, Wood DP, **Powell IJ**, Crissman JD, Pontes JE: Quantitative analysis of positive surgical margins and extra prostatic extension of prostate cancer (PCa) can improve the predictive power of pathologic stage for PSA failure in patients with clinically localized disease. J Urol 157(4): (Abstr), April 1997.
23. Littrup P, Grignon **D**, **Powell I**, Segel M, Klein R, Sakr W: Greater tumor involvement and higher Gleason scores on biopsies of African-American men. J Urol157(4) (Abstr), April 1997.
24. **Powell IJ**, Banerjee M, Sakr W, Grignon D, Novallo M, Honn K, Gao X, Wood D, Pontes J: Is prostate cancer testing at an earlier age among African American men versus Caucasian men appropriate? J Urol 157(4): (Abstr), April 1997.
25. Wood D, Sakr W, Grignon D, Swiriduk M, Novallo M, Cher M, **Powell I**, Pontes J: “Down staging” with neoadjuvant hormone treatment: the more organ confined prostate cancer (PCa) does not translate into lower PSA failure. J Urol 157(4): (Abstr), April 1997.
26. Lovisolo J, Grayson T, **Powell I**, Oldford G, Kuntzman M, Novallo M, Famiglietti G, Shekarriz B, Pontes J, Wood D: Results of a clinical care pathway for radical prostatectomy patients in a multi-physician-open hospital system. J Urol 157(4): (Abstr), April 1997.
27. Cher ML, Lewis PE, Sakr W, **Powell IJ**: Similar pattern of chromosomal alterations in prostate cancers from African Americans and Caucasian Americans. J Urol, Vol. 159, (5):, (Suppl), (Abstr #482, May 1998).
28. **Powell IJ**, Banerjee M, Novallo M, Sakr W, Wood D, Pontes JE: Should the age specific PSA cut-point for prostate biopsy be higher among African American vs. American Caucasian men above age 50 years. J Urol 159(5) (Suppl): (Abstr #280 May 1998).
29. **Powell IJ**, Banerjee M, Novallo M, Sakr W, Wood D, Pontes JE: Prostate cancer biochemical recurrence stage for stage is more frequent among African American vs. Caucasian men with locally advanced but not organ confined disease. J Urol, Vol. 159 (5): (Suppl), (Abstr #1138, May 1998).

30. Gheiler EL, Tiguert R, **Powell IJ**, Banerjee MJ, Pontes JE, Wood DP: Impact of positive surgical margins on disease free survival between African American and Caucasian men following radical prostatectomy. J Urol 161 (Abstr # 950), April 1999.
31. Sakr WA, Grignon DJ, Tiguert R, Banerjee M, **Powell IJ**, Pontes JE, Wood DP: Predictors of biochemical recurrence in pathologically organ-confined prostate cancer: analysis of preoperative PSA, age, race, Gleason score, tumor volume, PIN, DNA ploidy and proliferative activity. J Urol: 161, (Abstr # 1306), April 1999.
32. Narain V, Tiguert R, Banerjee M, Sakr W, Grignon D, Wood DP, Pontes JE, **Powell IJ**.. (Presented by Vivek Narain). Biochemical recurrence in African American and Caucasian men with a positive and negative family history of prostate cancer following radical prostatectomy. J Urol 163: (Abstr #240), April 2000.
33. **Powell IJ**, Sakr W, Weiss L, Haas G, Severson R. Detroit MI; Syracuse NY. (Presented by Isaac J. Powell). Prostate cancer is biologically more aggressive among African Americans than Caucasian men under age 70 years: Hypothesis supported by autopsy and seer data. J Urol 163: (Abstr #243), April 2000.
34. Sakr WA, Angelakis K, deGuia K, Cher M, Wood D, Grignon DJ, **Powell IJ** (Presented by Isaac W.A. Sakr). The prevalence and evolution of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) in African American (AA) and Caucasian (C) men – a study of needle biopsies. J Urol: 163 (Abstr #245), April 2000.
35. George V, Bianco, FJ, Domalles EJ, Cher ML, Wood DP, Sakr W, Pontes JE, **Powell IJ**. Predictors of biological aggressiveness of early prostate cancer. J Urol 163: (Abstr #247), April 2000.
36. Sakr W, deGuia GK, Grignon D, **Powell IJ**, Wood DP. Detroit, MI. Volume of “Index” tumor, number of tumor foci and distribution of high grade pin in radical prostatectomy specimens (RPS) between 1991-1999 J Urol 163: (Abstr #248), April 2000.
37. Bianco FJ, Cher ML, Beaman A, Nemeth JA, **Powell IJ**, Wood DP. Presence of circulating prostate cancer cells in African American males adversely affects disease free survival. J Urol 163: (Abstr #823), April 2000.
38. **Powell IJ**, Forman J, Chuba P, Cher M, Wood D, Dey J, Pontes JE. Detroit, MI An explanation for differences in survival between African Americans and Caucasians treated by radical prostatectomy and radiotherapy. J Urol 163: (Abstr #1439), April 2000.
39. **Powell IJ**, Nelson J, Severson R. The Impact of Socioeconomic Factors on PCA Outcome for Whites and African Americans. J Urol 165: (Abstr #262), August 2001.
40. Andea A, Dey J, deGuia K, Grignon DJ, Pontes JE, Wood DP, **Powell IJ**, Sakr W. Modeling prostate cancer distribution for exceedingly small tumor volumes in radical prostatectomy specimens: Implications for biopsy approach. J Urol 165: (Abstr #1275), August 2001
41. **Powell IJ**, Tangen CM, Haas GP, Crawford D, Miller GJ, Lowe, BA, Thompson IM, Neoadjuvant Zoladex and Flutamide in bulky and non-bulky clinical stage C carcinoma of the prostate. J Urol 165: (Abstr #1355), August 2001.

42. Bianco FJ, Wood DP, Grignon DJ, Sakr W, Pontes JE, **Powell IJ**. Presence of extraprostatic disease after radical prostatectomy diminishes survival significantly in African American men. *J Urol* 165: (Abstr #1356), August 2001
43. Bianco FJ, Wood DP, Pontes JE, Sakr W, Grignon DJ, **Powell IJ**, Detroit, MI "Prostate cancer stage shift has eliminated the gap in survival between African American and Caucasian men after radical prostatectomy. *J Urol* 232 ((Abstr #955), November 2001.
44. **Powell, IJ**, Bianco FJ, Dey J, Wood DP. Race/ethnicity as an independent predictor of prostate cancer outcome is conditional" *J Urol* 167: (Abstr #28), April 2002.
45. Bianco FJ, Kattan M, Scardino PT, **Powell, IJ**, Pontes E, Wood DP. Validation of Kattan preoperative and postoperative nomograms in African-American men with prostate cancer. *J Urol*,167:(Abstr #413), April 2002.
46. Bianco FJ, Cher MC, **Powell IJ**, Grignon DJ, Sakr WA, Wood DP, Pontes JE. Specimen Gleason score is the only prognostic factor in pathologically organ confined prostate cancer. *J Urol* 167: (Abstr #1408), April 2002.
47. Powell IJ, Land SJ, Dey J, Sakr WA, Hughes M, Everson R, Zhou JY, Sun Y. CYP3A4 genetic variant and survival analysis among a diverse population of men undergoing radical prostatectomy. *J Urol* 169: (Abstr #291) ,April 2003.
48. Ahaghotu C, Baffoe-Bonney A, Kittles R, Pettaway C, **Powell I**, Royal C, Vijayakumar S, Bennett J, Hoke G, Mason T, Bailey-Wilson J, Boykin W, Berg K, Carpten J, Weinrich S, Trent J, Duston G, Collins F. Clinical characteristics of the African American hereditary prostate cancer study cohort. *J Urol* 169: (Abstr #282), April 2003.
49. Fisher MB, Bianco FJ, Sakr WA, Everson R, **Powell IJ**. Variant of CYP3A4 associated with recurrence of androgen independence in prostate cancer. *J Urol* 169: (Abstr #1442), April 2003.
50. Davis DE, Underwood W, Gonzalez H, **Powell IJ**, Wood DP Jr. Geographic and demographic Variations in the use of pelvic lymph node dissection in men diagnosed with clinically localized prostate cancer. *J Urol* 171: (Abstr#157), April 2004.
51. Underwood W III, **Powell IJ**, Davis DE, Gonzalez H, DeMonner S, Sanda MJ, Wei JT. Racial variations in the utilization of pelvic lymph node dissection in men receiving a radical prostatectomy for localized/ regional prostate cancer. *J Urol* 171: (Abstr# 473), April 2004.
52. **Powell IJ**, Sakr WA, Butler C, Zhou JY, Sun Y, Wang C, Patel NP, Heilbrun L, Everson R. Impact of the SRD5A2 A49T genetic polymorphism on progression after prostatectomy among Caucasian and African American men. *J Urol* 171: (Abstr# 833), April 2004.
53. Sakr WA, Grignon D, Che M, Kolizeras K, Andea A, **Powell IJ**, Cher ML, Pontes JE. PSA and pathological parameters of needle biopsy (BX) and radical prostatectomy specimens (RPS) across the age spectrum of African American (AA) and Caucasian(C) Men: An analysis of 3049 BX and 1862 RPS. *J Urol* 171: (Abstr# 1187), April 2004.

54. Bianco FJ, Fisher MB, Cher ML, Everson R, Sarkr WA, **Powell IJ**. Androgen metabolism genotypes as predictors of PSA progression and first line hormonal deprivation failure. J Urol 171: (Abstr #1664), April 2004.
55. Williams, H., **Powell, I.J.**, Land, S.J., Sakr, W.A., Hughes, M.R., Patel, N.P., Heilbrun, L.K., Everson, R.B. Vitamin D receptor gene polymorphisms and disease-free survival after radical prostatectomy. The Prostate, 61(3): 267-275, (Abstr) 2004.
56. **Powell IJ**, Everson R, Fisher M, Banerjee M. African American men, ages 40-59, unlike Caucasian men, present with as aggressive PCA as older African Americans: A genetic explanation. J Urol 173(4) (Suppl): (Abstr#269) 2005.
57. **Powell IJ**, Fisher M, Sun Y, Everson RB. Macrophage scavenger receptor 1 gene (MSR-1) poly-morphisms and progression after prostatectomy. J Urol 173(4), (Suppl): (Abstr #1410), May 2005
58. **Powell IJ**, Baffoe B, Carpten J, XU J, Salem W, William I, Disparity and similarity in hereditary prostate cancer among African Americans and Europeans Americans: largest genome-wide linkage studies. J Urol (Abstr 453) (5), 2007.
59. **Powell IJ**, Williams H, Bock C, Heath M, Sakr W. Impact of apical surgical margin status on disease progression in men with localized prostate cancer treated with radical reteopublic prostectomy, J Urol (Abstr 1409) (5), 2007.
60. **Powell IJ**, Heath E, Kattan M, Sakr W, Brand T, Rybicki B, Thompson I, William A, Terris W, Kane C, Presti J, Amling C, Freedland S. Are partin tables accurate for African American men in the United States. J Urol (Abstr #328): (5), 2007.
61. Klink JC, Banez LL, **Powell IJ**, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freeland SJ. T1C disease in black men: A more aggressive disease results from the search database. J Urol (Abstr #1897) 179(4), 2008
62. **Powell IJ**, Bock C, Ruterbusch J, Sakr W, Clinical evidence supports a faster growth rate for prostate cancer among African Americans compared to European American men. J Urol (Abstr # 170) (4) 2009
63. Williams H, Ross I, Popovic M, Posey Z, **Powell IJ**. Racial differences in clear cell renal cell carcinoma presentations and survival. . J Urol (Abstr # 1232) (4) 2009
64. **Powell IJ**, Ruterbusch J, Schwartz A, Bock C. Evidence in support of earlier PSA testing in African American men age 35 . J Urol (Abstr # 1782) (4) 2009
65. Bonilla C, Bock C, Ahaghotu C, Ruterbusch J, Kittles R, **Powell IJ**. CYP3A gene cluster, population stratification, and prostate cancer risk. . J Urol (Abstr # 2258) (4) 2009
66. **Powell IJ**, Schwartz A, Land S, Bock C, Ruterbusch J, Beebe-dimmer J, Lenk S, Everson R, Giroux C. Is There a different gene expression profile for African American men versus European American men? J. Urol. (Abstr.# 250) (4) 2010.
67. **Powell IJ**, Vigneau FD, Ruterbusch J, Heilbrun LK, Bock C. Earlier age for prostate cancer screening of African American men is needed to eliminate racial mortality disparity. J. Urol. Annual Meeting (Abstr. # 1201) 2011.

68. **Powell IJ**, Dyson G, Land S, Ruterbusch J, Bock C, Lenk S, Everson R, Giroux C. A panel of hub genes associated with aggressiveness and biochemical recurrence after radical prostatectomy are more highly expressed among African American than European American men. J. Urol. Annual Meeting (Abstr. # LBA3) 2012.
69. **Powell IJ**, Heilbrun L, Smith D, Bolton, S, Kieley S, Bock C. An update of progression free survival (PFS) of locally advanced prostate cancer among African American and European American men who have undergone radical prostatectomy. J. Urol Annual Meeting (Abstr # 1635) 2012.
70. **Isaac Powell**, Greg Dyson, Aliccia Bolig-Fischer: ERG as a Potential Biomarker for Prostate Cancer May Benefit European American Men But Not African American Men. AUA abstract 2238

PRESENTATIONS:

1. **Powell IJ**, Littleton R, Cerny, JC: Ultrasonic Treatment of Peyronies Diseases. Presented to North Central American Urological Association Meeting, Nov. 1973.
2. **Powell IJ** and Cerny JC: Vesico-Enteric Fistula. Presented at Residents Day, Detroit Branch, American Urological Society, 1974.
3. Klugo RC, Reid R, **Powell IJ**, and Cerny JC: Xanthogranulomatous Pyelonephritis in Children. Presented to International Symposium of Pediatric Nephrology. March 1977.
4. **Powell IJ**, Littleton R, and Cerny JC: Ultrasonic treatment of peyronies disease. Presented to Annual Meeting of American Urological Association. May 1980.
5. **Powell IJ** and Hollowell ML: Urethral Diverticula of the female. Presented to North Central Section of American Urological Association 1982.
6. Tyrkus M, **Powell IJ** and Guy W: Chromosomal Changes in Long-Term TCC Culture: Predictive Value. Poster Presentation to the American Society of Human Genetics. Nov. 1986.
7. **Powell IJ**, Tyrkus M, Ghayad P, Guy W, Pierce JM: Cytogenetics: Use in Prognosis and Management of Bladder Cancer. Presented at the Annual Meeting of The North Central Section of American Urological Association, Inc. Nov. 1986.
8. **Powell IJ**: Comparison of Prognostic Indicators Bladder Tumor Development. Presented to the Michigan Branch of American Urological Association. March 1987.
9. **Powell IJ**, Tyrkus M, Ghayad P, Guy W, Pierce JM: Cytogenetics: Use in Prognosis and Management of Bladder Cancer. Presented at the Annual Meeting of the American Urological Association, Inc. May 1987.
10. **Powell IJ**, Tyrkus M, Guy WL, and Pierce JM: Cytogenetics of Carcinoma in Situ: An Important Determinant in Prognosis. Presented to the North Central Section of American Urological Association. Sept. 1987.
11. **Powell IJ**, Fleming C, Tyrkus M, Pierce JM: Comparison of Cytogenetics and Flow Cytometry in Transitional Cell Carcinoma. Presented to the North Central Section of American Urological Association. Sept. 1987.

12. **Powell IJ**, Fleming C, Tyrkus M, Pierce JM: Comparison of Cytogenetics and Flow Cytometry in Transitional Cell Carcinoma. Presented to the 26th Annual Somatic Cell Genetics Conference, Traverse City, MI. Jan, 1988.
13. **Powell IJ**. Genetics of Bladder Cancer. Presented to the MI Osteopathic Urological Group, April 1988.
14. **Powell IJ**. Defined Standards of Care, Its Impact on Malpractice. Presented to the Michigan Urological Society Meeting, Harper Hospital, Kresge Auditorium, September 1988.
15. **Powell IJ**. Loss of the sex chromosome in bladder cancer. Is there a clinical significance? Presented at North Central Section, AUA, November 1988.
16. **Powell IJ**: Genitourinary Cancer. Presented to the Oakwood Hospital Family Practice Residency Program, January, 1989.
17. **Powell IJ**. Filming of Health Matters segment on "Prostate Cancer" - aired on Channel 56 on June 25 and June 30, 1989, Detroit, MI.
18. **Powell IJ** and Tyrkus M: Evaluation of the Relative Accuracy of Chromosome Findings in Short Term Cultures vs. Long Term Cultures of Bladder Cancer. Presented at North Central Section, American Urological Association, Inc., September 1989.
19. **Powell IJ**, Tyrkus M and Gohle N: Cytogenetic Studies of TCC of the Bladder: Correlation of Karyotype, Aggressive Nature and Disease Course. Presented at the Annual Meeting of the American Society of Human Genetics, 1989.
20. **Powell IJ**, Ensley J, Hussain M, Sakr W, Wolman S, Lane MA, Mohammed A, Macoska J: Molecular Genetic, Cytogenetic, and Flow Cytometry Analysis in Patients Undergoing Radical Prostatectomy for Carcinoma of the Prostate Gland. Presented at the 64th Annual Meeting of the North Central Section American Urological Association, Inc., October 26, 1990.
21. **Powell IJ** and Tyrkus M: Cytogenetic Studies of Carcinoma In Situ (CIS) of the Bladder. Presented at the 64th Annual Meeting of the North Central Section American Urological Association, Inc., October 27, 1990.
22. Wolman SR, Mohammed A, Micale MA, Macoska JA, Lane MA, and **Powell IJ**: Cytogenetic and Molecular Studies of Primary Prostatic Adenocarcinomas. Presented at the Fourth International Workshop on Chromosomes in Solid Tumors, February 24-26, 1991.
23. Macoska JA, **Powell IJ**, and Lane MA: Molecular Genetic Alterations in Human Prostate Carcinoma. Presented at the Society for Basic Urologic Research 1991 Annual Meeting in Toronto, Ontario, Canada, June 1, 1991.
24. Micale MA, Mohammed A, **Powell IJ**, Wolman SR, Pontes JE: Genetic Instability in Adenocarcinoma of the Prostate. Presented at the Society for Basic Urologic Research 1991 Annual Meeting in Toronto, Ontario, Canada, June 1, 1991.
25. Tyrkus M and **Powell IJ**: Cytogenetic Studies of CIS of the Bladder: Prognostic Implications. Presented at the 1991 American Urological Association Meeting in Toronto, Ontario, Canada, June 2-6, 1991.

26. Micale MA, Mohammed A, **Powell I**, Wolman SR, Pontes JE: Genetic Instability in Adenocarcinoma of the Prostate. Society for Basic Urologic Research, Platform Presentation, June, 1991.
27. **Powell I**, Macoska JA, Micale MA, Mohammed A, Rowe IA, Lane MA, Wolman SR: Molecular Genetic and Karyotypic Alterations in Prostate Carcinoma. Presented at the 8th International Congress of Human Genetics, Washington, D.C. October 1991.
28. **Powell, IJ**, Gimotty P, Wolman SH, Micale MA, Betrus J, Pontes JE: Clinical and cytogenetic correlations and trends in prostate cancer. Presented at the 1992 American Urological Association Meeting in Washington, D.C., May 10-14, 1992.
29. Micale M, Sanford J, Sakr W, **Powell IJ**, Wolman S: Intra-and-inter-glandular genetic heterogeneity revealed by fluorescence in situ hybridization in prostatic adenocarcinoma. Presented at the 1993 Fifth International Workshop on Chromosomes in Solid Tumors in Tucson, Arizona, January 10-12, 1993.
30. Turkeri LN, Macoska JA, Sakr W, Micale MA, **Powell IJ**, and Pontes JE: Combined PCR and Fish analysis of Y chromosome loss related to age and disease status in prostate cancer presented at the Society for Basic Urologic Research 1993 Annual Meeting in San Antonio Texas, May 15, 1993.
31. **Powell IJ**, Gelfand D, Parzuchowski J, Franklin A, Montie J: Overcoming barriers to early detection in the African American Community; (DEED Program: Detroit Education and Early Detection). Annual Meeting of AUA, May 1994.
32. **Powell IJ**, Schwartz K, Hussain M: Stage of presentation of African American and Caucasian men with prostate cancer at a VA Hospital. Annual Meeting of AUA, May 1994.
33. **Powell IJ**, Kumar A, Montie JE, Haas GP, Sakr W, Grignon D, Heilbrun L. Pontes JE: Prognostic factor variations between African American Men and Caucasian Men with clinical localized prostate carcinoma. Annual Meeting of AUA, May 1994.
34. **Powell IJ**: African American Study: American Cancer Society National Conference on Prostate Cancer, September 1994.
35. **Powell IJ**: Racial and Ethnic Factors Related to Prostate Cancer: American Association for Cancer Research Conference, Palm Springs, California, December, 1994.
36. Filming of Health Matters Segment on "Cancer in Men" aired on Channel 56 on April 25 and 29, 1995, Detroit.
37. International Conference on Prostate Cancer Early Detection and Control. Atlanta, September 6-7, 1995.
38. **Powell IJ**: A successful recruitment model for African American men: the DEED program. Conference on the recruitment and retention of minority participants in clinical cancer research, Washington, D.C., January 26-27, 1996.
39. **Powell IJ**. American College of Surgeons 84th Clinical Congress Meeting, Wednesday, October 28, 1998, in Orlando, Florida. Title: Screening for Prostate Cancer: Pros and Cons: Screening for Prostate Cancer in African Americans.

40. **Powell, IJ.** American Association for Cancer Research, Inc., 90th Annual Meeting, April 10-14, 1999, in Philadelphia, PA. Title: Biological disparities in prostate cancer among African Americans.
41. **Powell, IJ.** Great Lakes Urology Seminar, March 12-13, 1999, in Detroit, Michigan. Title: Prostate Cancer in African American Men.
42. International Conference on Prostate Cancer Research, June 24-27, 1999, in Iowa City, Iowa. Title: Prostate Cancer Epidemiology: Racial/Ethnic Variations and Molecular Factors.
43. Seminar on Biological/Translational Research in Prostate Cancer among African American Men, funded by NCI, June 1999. Title: An Overview of Prostate Cancer in African Americans.
44. National Medical Association Annual Meeting Aug. 1999, Las Vegas, Nevada. Title: African American Hereditary Prostate Cancer Study: Recruitment Process.
45. Strategies for Developing New Clinical Trails for Prostate Cancer Prevention, Aug 1999, (NCI Funding). Title: High Risk Prostate Cancer: African American Males.
46. 8th Prouts Neck Meeting on Prostate Cancer. Etiology and Prevention: Panelist, October, 1999.
47. Visiting Professor, Farmington, Connecticut. "Clinical Epidemiology" and "Clinical Molecular Epidemiology". June 22,2000.
48. Symposium "Prostate Cancer in Minority Populations: Biological Factors". Prostate Cancer: An Overview of the Issues. NIH and Virginia Commonwealth University. Jun 2-3, 2000.
49. Forum on Prostate Cancer of the 21st Century. Los Angeles, California. "Molecular Epidemiology". April 7-8, 2000.
50. Prostate Cancer in the African American Community: Prostate Cancer Screening, Treatment and Clinical Outcomes Sponsored by Bayer Pharmaceuticals February 2-3, 2001, Washington D.C.
51. University of Michigan G.U. Oncology Conference: Clinical and Molecular Epidemiology Prostate Cancer February 20, 2001.
52. Visiting Professor of SUNY upstate Medical University: Ethnical Differences in Prostate Cancer. February 28 – March 1, 2001.
53. Great Lakes Urology Seminar: Recommendation for Prostate Cancer Screening based on Epidemiology and genetic markers. March 16-17, 2001
54. First California Cancer Research Program Symposium: Prostate Cancer in African American Men. April 17-18, 2001.
55. American Cancer Society, Cleveland Ohio: Update of basic knowledge of diagnostic risk factors of prostate cancer and hereditary prostate cancer and current treatment outcome of prostate cancer among African Americans. June 22, 2001.
56. International consortium on Prostate Cancer Genetics Group: Update on the African American Hereditary Prostate Cancer Study. July 11-12, 2001.

57. WKBD UPN Channel 50 Straight Talk Program: Prostate Cancer. July 18, 2001.
58. National Medical Association Annual Meeting: Prostate Cancer Screening pro and con. August 9-12, 2001.
59. National Medical Association Annual Meeting: The Role of Genetics in Prostate Cancer Ethnic Disparity 2). Select Trials Update 3). Clinical Prostate Cancer, 2002. A:/Powell/CV(Updated 4-23-02)
60. American Cancer Society Health Disparity Conference; lecture Molecular and Clinical Epidemiology of Prostate Cancer, 2007.
61. Black Health Care Coalition, Inc; lecture, Eliminating Cancer Disparities among African American, 2007.
62. Michigan State Legislators; lecture, Ethnic Differences in The Biology of Prostate Cancer. 2007.
63. Karmanos Cancer Institute, Detroit, MI; lecture, Prostate Cancer among African American and European Americans, 2007.
64. American Urological Association, Annual Meeting, African American Heredity Prostate Cancer, Disparities and Similarities. The largest genome-wide study, May 2007.
65. American Urological Association Foundation, Prostate Cancer DV, "What Do You Know About Prostate Cancer", 2007.
66. American Urologic Association annual meeting, "Clinical evidence supports a faster growth rate for prostate cancer among African Americans compared to European American men". April 2009
67. American Urologic Association annual meeting, "Evidence in support of earlier PSA testing in African American men age 35". April 2009
68. Morehouse Prostate Cancer Conference. "State of prostate health in America"
69. National Medical Association. Las Vegas "Prostate cancer metabolic syndrome and the African American male" July 2009
70. Prostate Cancer Symposium, New York, 1. Advanced stage prostate cancer 2, Primary therapeutic protocols. Oct 2009
71. First National Conference on Cancer Control, Kuwait. 1. "Screening/early detection of prostate cancer", 2. Treatment of locally advanced prostate cancer", 3. "Prostate cancer prevention trial (PCPT)" Nov 2009
72. American Urologic Association annual meeting, San Francisco, Calif. "Is there a different gene expression profile for African American men versus European American men?" May 2010.
73. Congressional Prostate Cancer Awareness Symposium, Wash. DC. Genetic causation for prostate cancer mortality disparity among young African American men. June 2010.
74. International Consortium Prostate Cancer Genetics presentation, Paris France. Prostate cancer growth kinetics in African American men. June, 2010.
75. The Science of Global Prostate Cancer Disparities in Black Men, Jacksonville, Fla. 1. Prostate cancer outcomes. 2. Geographical and Outcome Variation: Racial differences in prostate cancer outcomes. August, 2010.

76. Department of Defense ImPact meeting. Orlando Fla. Clinical and genetic evidence support a faster growth rate for prostate cancer among African American compared to European American men. Feb. 2011
77. American Urologic Association annual meeting, PAUSA society presentation, Washington DC Metabolic syndrome and prostate cancer . May 2011.
78. American Urologic Association annual meeting, Washington DC Earlier age for prostate cancer screening of African American men is needed to eliminate racial mortality disparity. May 2011.
79. NIH meeting: Workshop on Prostate Cancer in Men of African Descent. Section Chair: What do we know about prostate cancer in men of African descent and what do we need to know? Presentation: Clinical evidence support a faster growth rate for prostate cancer among African American compared to European American men. Oct. 2011
80. American Urologic Association annual meeting, Atlanta, Ga. An update of progression free survival (PFS) of locally advanced prostate cancer among African American and European American men who have undergone radical prostatectomy. May 2012.
81. American Urologic Association annual meeting, Atlanta GA. A panel of hub genes associate with aggressiveness and biochemical recurrence after radical prostatectomy are more highly expressed among African American that European American men May 2012.
82. Society of Basic Urologic Research June 2012: The Dynamic of Prostate Cancer Among African American Compared to European American Men
83. 3rd Annual Prostate Cancer Symposium, Northwestern Univ./Univ. of Chicago Sept 2012: Why Do African Americans Have More Advanced Prostate Cancer
84. AUA annual meeting. ERG as a Potential Biomarker for Prostate Cancer May Benefit European American Men But Not African American Men. May 2013
85. American Association of Cancer Research, Atlanta Ga. Prostate Cancer Screening Debate. Dec. 2013
86. University of California, Irvine "Clinical, Genetic and Molecular Biology Among African American Compared to European American Men" January 2014
87. Medical Univ. of South Carolina "Clinical and Molecular Biology of Prostate Cancer among African American Compared to European Americans" March 2014
88. Clark Atlanta University 10th Annual National Symposium on Prostate Cancer "Genes Associated with Prostate Cancer are Differentially Expressed in African American and European American Men" March 2014
89. AUA annual meeting Orlando Fl.: AUA Early Detection of the Prostate Guidelines. May 2014
90. AUA annual meeting Orlando Fl.: Round Table Discussion: Prostate Cancer Screening and the USPSTF' Recommendations: Identifying GAP's For Potential Research Opportunities. May 2014.
91. 21st Annual Prostate Cancer Foundation Scientific Retreat: Special Lecture: "Prostate Cancer Molecular Biomarker Development Among African American and European American Men" October 2014
92. 2014 Biennial Science of Global Prostate Cancer, Montego Bay, Jamaica: "Prostate Cancer Molecular Biomarker Development Among African American compared to European Americans" November 2014

93. 4th Florida Prostate Cancer Research Symposium: "Prostate Cancer Screening: Challenges and Opportunities" April 2015
94. The University of Mississippi Medical Center 2015 Prostate Cancer Research Mini Symposium: "Prostate Cancer Molecular Biomarker Development Among African American Compared to European American Men". July 2015
95. R. Frank Jones Urological Society 2015 Annual Meeting at the National Medical Association: "Biology of Prostate Cancer and Its Impact on Clinical Outcome Among AAM Compared to EAM". Aug. 2015
96. R. Frank Jones Urological Society 2015 Annual Meeting at the National Medical Association: "Prostate Cancer Screening: Firestorm Controversy". Aug. 2015
97. PHEN Eleventh Annual Summit: "Research Basis for the Concept: Prostate Cancer Grows Faster Among African American Compared to European American Men" Sept. 2015
98. Society of Basic Urologic Research: "Biology of Prostate Cancer and Its Impact On Clinical Outcome Among African American Compared to European American Men" November 2015
99. Eighth American Association for Cancer Research Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved: "Biological Bases of Prostate Cancer Disparities in African American Men" November 2015